| pubmed-article:8823338 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8823338 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8823338 | lifeskim:mentions | umls-concept:C0678222 | lld:lifeskim |
| pubmed-article:8823338 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:8823338 | lifeskim:mentions | umls-concept:C0026259 | lld:lifeskim |
| pubmed-article:8823338 | lifeskim:mentions | umls-concept:C0210630 | lld:lifeskim |
| pubmed-article:8823338 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:8823338 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:8823338 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:8823338 | pubmed:dateCreated | 1996-10-30 | lld:pubmed |
| pubmed-article:8823338 | pubmed:abstractText | To determine the maximum-tolerated dose (MTD) of mitoxantrone that could be safely used in combination with cyclophosphamide and filgrastim in patients with advanced breast carcinoma. | lld:pubmed |
| pubmed-article:8823338 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8823338 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8823338 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8823338 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8823338 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8823338 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8823338 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8823338 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8823338 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8823338 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8823338 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8823338 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:8823338 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:8823338 | pubmed:author | pubmed-author:SilvermanPP | lld:pubmed |
| pubmed-article:8823338 | pubmed:author | pubmed-author:LazarusHH | lld:pubmed |
| pubmed-article:8823338 | pubmed:author | pubmed-author:MalikUU | lld:pubmed |
| pubmed-article:8823338 | pubmed:author | pubmed-author:RobertNN | lld:pubmed |
| pubmed-article:8823338 | pubmed:author | pubmed-author:SparanoJ AJA | lld:pubmed |
| pubmed-article:8823338 | pubmed:author | pubmed-author:SartaCC | lld:pubmed |
| pubmed-article:8823338 | pubmed:author | pubmed-author:VenkatrajUU | lld:pubmed |
| pubmed-article:8823338 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8823338 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:8823338 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8823338 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8823338 | pubmed:pagination | 2576-83 | lld:pubmed |
| pubmed-article:8823338 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:8823338 | pubmed:meshHeading | pubmed-meshheading:8823338-... | lld:pubmed |
| pubmed-article:8823338 | pubmed:meshHeading | pubmed-meshheading:8823338-... | lld:pubmed |
| pubmed-article:8823338 | pubmed:meshHeading | pubmed-meshheading:8823338-... | lld:pubmed |
| pubmed-article:8823338 | pubmed:meshHeading | pubmed-meshheading:8823338-... | lld:pubmed |
| pubmed-article:8823338 | pubmed:meshHeading | pubmed-meshheading:8823338-... | lld:pubmed |
| pubmed-article:8823338 | pubmed:meshHeading | pubmed-meshheading:8823338-... | lld:pubmed |
| pubmed-article:8823338 | pubmed:meshHeading | pubmed-meshheading:8823338-... | lld:pubmed |
| pubmed-article:8823338 | pubmed:meshHeading | pubmed-meshheading:8823338-... | lld:pubmed |
| pubmed-article:8823338 | pubmed:meshHeading | pubmed-meshheading:8823338-... | lld:pubmed |
| pubmed-article:8823338 | pubmed:meshHeading | pubmed-meshheading:8823338-... | lld:pubmed |
| pubmed-article:8823338 | pubmed:meshHeading | pubmed-meshheading:8823338-... | lld:pubmed |
| pubmed-article:8823338 | pubmed:meshHeading | pubmed-meshheading:8823338-... | lld:pubmed |
| pubmed-article:8823338 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8823338 | pubmed:articleTitle | Phase I trial of high-dose mitoxantrone plus cyclophosphamide and filgrastim in patients with advanced breast carcinoma. | lld:pubmed |
| pubmed-article:8823338 | pubmed:affiliation | Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, NY 10467, USA. Sparano@Jimmy.harvard.edu | lld:pubmed |
| pubmed-article:8823338 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8823338 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8823338 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8823338 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:8823338 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
